<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088330</url>
  </required_header>
  <id_info>
    <org_study_id>D-VRD-MM05</org_study_id>
    <nct_id>NCT05088330</nct_id>
  </id_info>
  <brief_title>A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM</brief_title>
  <official_title>A Prospective Study of Daratumumab Combined With VRD in the Treatment of Patients With Newly Diagnosed Standard-risk Multiple Myeloma : a Single-center, Single-arm Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm study to access the effect of treatment with D-VRD in&#xD;
      patients with newly diagnosed standard risk multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research object:Newly diagnosed standard-risk multiple myeloma (NDMM) diagnosed according to&#xD;
      the International Myeloma Working Group (IMWG) standards and who have been assessed to&#xD;
      receive Autologous Stem Cell Transplantation (ASCT) but actively refused.Objective: To&#xD;
      explore the therapeutic options of daratumamab (D) combined with bortezomib (V), lenalidomide&#xD;
      (R) and dexamethasone ( d) for objective assessment of patients who can receive ASCT but not&#xD;
      to receive transplantation.Main indicators:negative rate of minimal residual disease (MRD)&#xD;
      upon completion of cycle 8 (24 weeks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>D-VRD</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of minimal residual disease negativity</measure>
    <time_frame>end of 8 cycles</time_frame>
    <description>rate of minimal residual disease negativity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Newly Diagnosed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>D-VRD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with D-VRD in NDMM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>treatment with D-VRD in NDMM</description>
    <arm_group_label>D-VRD</arm_group_label>
    <other_name>DARA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age ≥ 18 years and ≤ 70 years, male or female；&#xD;
&#xD;
          2. Newly diagnosed multiple myeloma (NDMM) ；&#xD;
&#xD;
          3. Transplant-eligible；&#xD;
&#xD;
          4. Non-17p-, t(4;14) , t(14;16)；&#xD;
&#xD;
          5. Expected survival ≥12 weeks;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) scores 0 - 2.&#xD;
&#xD;
          7. Subjects should have adequate hemostatic and liver and kidney meet the following&#xD;
             examination criteria: (without ongoing supportive treatments):&#xD;
&#xD;
               1. Complete blood count (CBC) results: absolute neutrophil count（ANC） ≥ 1.0 × 109/L,&#xD;
                  platelet count ≥ 75 × 109/L (if the proportion of plasma cells in the bone marrow&#xD;
                  is &gt; 50%, subjects with platelets ≥ 50 × 109/L will be eligible), Hb ≥ 70 g/L.&#xD;
&#xD;
               2. Blood biochemistry: creatinine clearance ≥ 30 mL/min, alanine aminotransferase&#xD;
                  (ALT) ≤ 2.5 × upper limit normal (ULN)，aspartate aminotransferase (AST) ≤ 2.5 ×&#xD;
                  ULN, total bilirubin ≤ 1.5 × ULN. Serum calcium ≤14.0 mg/dL (≤3.5 mmol/L);&#xD;
&#xD;
          8. Normal cardiopulmonary function;&#xD;
&#xD;
          9. The patient agrees to join the clinical trial and signs an informed consent form.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Poor hypertension control;&#xD;
&#xD;
          2. Have received ASCT or anti-tumor systemic therapy;&#xD;
&#xD;
          3. Peripheral neuropathy or neuralgia of grade 2 or higher;&#xD;
&#xD;
          4. During pregnancy or lactation or planning to become pregnant;&#xD;
&#xD;
          5. History of other malignant tumors within 5 years;&#xD;
&#xD;
          6. Subjects positive for any following tests: human immunodeficiency virus (HIV)&#xD;
             antibody, Treponema pallidum (syphilis) antibody, hepatitis C virus (HCV) antibody,&#xD;
             hepatitis B virus (HBV) surface antigen (HBsAg) and HBV DNA.&#xD;
&#xD;
          7. Participating in other clinical trials;&#xD;
&#xD;
          8. Allergic to the drugs in the treatment plan;&#xD;
&#xD;
          9. Receiving any other experimental drugs or experimental medical devices;&#xD;
&#xD;
         10. The investigator believes that the patient has other conditions that are not suitable&#xD;
             for participating in this study.&#xD;
&#xD;
         11. Patients with R-ISS Phase III&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Soochow University</investigator_affiliation>
    <investigator_full_name>Fu chengcheng PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

